Logo
x

Search

Subscribe Now

Vertex

PharmaShots Weekly Snapshots (April 08 – April 12, 2024)

PharmaShots Weekly Snapshots (April 08 – April 12, 2024)

  • April 12, 2024
Vertex to Acquire Alpine Immune Sciences for ~$4.9B

Vertex to Acquire Alpine Immune Sciences for ~$4.9B

  • April 11, 2024
Vertex Receives CHMP’s Positive Opinion for Kalydeco as a Treatment of Cystic Fibrosis in Infants

Vertex Receives CHMP’s Positive Opinion for Kalydeco as a Treatment of Cystic Fibrosis in Infants

  • February 23, 2024
Insights+: EMA Marketing Authorization of New Drugs in November 2023

Insights+: EMA Marketing Authorization of New Drugs in November 2023

  • December 29, 2023
Vertex’s Kaftrio+Ivacafor Receives EC’s Approval for the Treatment of Children aged 2 to 5yrs. with Cystic Fibrosis (CF)

Vertex’s Kaftrio+Ivacafor Receives EC’s Approval for the Treatment of Children aged 2 to 5yrs. with Cystic Fibrosis (CF)

  • November 24, 2023
Vertex and CRISPR Therapeutics Received MHRA’s Authorization for Casgevy to Treat Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex and CRISPR Therapeutics Received MHRA’s Authorization for Casgevy to Treat Sickle Cell Disease and Transfusion-Dependent Be...

  • November 16, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.